Prescribing controlled substances in sleep medicine clinics: an overview of legal issues and best safety practices.

IF 3.5 3区 医学 Q1 CLINICAL NEUROLOGY
Bhanu Prakash Kolla, Michael H Silber, David R Rushlow, Kannan Ramar, Meghna P Mansukhani
{"title":"Prescribing controlled substances in sleep medicine clinics: an overview of legal issues and best safety practices.","authors":"Bhanu Prakash Kolla, Michael H Silber, David R Rushlow, Kannan Ramar, Meghna P Mansukhani","doi":"10.5664/jcsm.11770","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objectives: </strong>This review describes the legal and regulatory landscape surrounding controlled substance prescribing in sleep medicine, focusing on the Controlled Substance Act (CSA), Drug Enforcement Agency (DEA), and best practices. It explores abuse and dependence risks associated with these medications and addresses telemedicine and e-prescribing considerations.</p><p><strong>Methods: </strong>We synthesized information from the CSA, DEA, Centers for Disease Control and Prevention, Federation of State Medical Boards, peer-reviewed medical literature, and professional organizational position statements regarding controlled substances in sleep medicine.</p><p><strong>Results: </strong>Managing controlled substances in sleep medicine necessitates careful consideration of DEA scheduling, regulatory requirements, and potential risks. Opioids pose a risk of dependence or abuse, but the lower doses used in sleep medicine may mitigate this risk. There is less evidence available regarding the abuse potential of stimulants. Hypnotics and benzodiazepines require cautious prescribing due to the potential for long-term use by patients and possibility of dose escalation. Oxybates are subject to strict Risk Evaluation and Mitigation Strategy programs. Best practices include comprehensive patient evaluations, thorough risk assessments, Prescription Drug Monitoring Program checks, and transparent patient communication. Telemedicine prescribing is governed by strict regulatory statutes, with temporary exceptions currently in place.</p><p><strong>Conclusions: </strong>Controlled substances are vital for managing various sleep disorders. Balancing patient access to effective medications while minimizing abuse and diversion is crucial. Further research is needed to refine risk assessment tools and develop standardized protocols, particularly for non-opioids. The evolving role of telemedicine and e-prescriptions requires ongoing evaluation and adaptation of practices to ensure patient safety and regulatory compliance.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5664/jcsm.11770","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Study objectives: This review describes the legal and regulatory landscape surrounding controlled substance prescribing in sleep medicine, focusing on the Controlled Substance Act (CSA), Drug Enforcement Agency (DEA), and best practices. It explores abuse and dependence risks associated with these medications and addresses telemedicine and e-prescribing considerations.

Methods: We synthesized information from the CSA, DEA, Centers for Disease Control and Prevention, Federation of State Medical Boards, peer-reviewed medical literature, and professional organizational position statements regarding controlled substances in sleep medicine.

Results: Managing controlled substances in sleep medicine necessitates careful consideration of DEA scheduling, regulatory requirements, and potential risks. Opioids pose a risk of dependence or abuse, but the lower doses used in sleep medicine may mitigate this risk. There is less evidence available regarding the abuse potential of stimulants. Hypnotics and benzodiazepines require cautious prescribing due to the potential for long-term use by patients and possibility of dose escalation. Oxybates are subject to strict Risk Evaluation and Mitigation Strategy programs. Best practices include comprehensive patient evaluations, thorough risk assessments, Prescription Drug Monitoring Program checks, and transparent patient communication. Telemedicine prescribing is governed by strict regulatory statutes, with temporary exceptions currently in place.

Conclusions: Controlled substances are vital for managing various sleep disorders. Balancing patient access to effective medications while minimizing abuse and diversion is crucial. Further research is needed to refine risk assessment tools and develop standardized protocols, particularly for non-opioids. The evolving role of telemedicine and e-prescriptions requires ongoing evaluation and adaptation of practices to ensure patient safety and regulatory compliance.

在睡眠医学诊所处方受控物质:法律问题和最佳安全实践的概述。
研究目的:本综述描述了睡眠药物中受控物质处方的法律和监管环境,重点是受控物质法案(CSA),缉毒局(DEA)和最佳实践。它探讨了与这些药物相关的滥用和依赖风险,并讨论了远程医疗和电子处方的考虑因素。方法:我们综合了来自CSA、DEA、疾病控制和预防中心、国家医学委员会联合会、同行评议的医学文献和有关睡眠医学中受控物质的专业组织立场声明的信息。结果:管理睡眠药物中的受控物质需要仔细考虑DEA的调度、监管要求和潜在风险。阿片类药物存在依赖或滥用的风险,但在睡眠药物中使用的低剂量可能会减轻这种风险。关于兴奋剂可能被滥用的证据较少。催眠药和苯二氮卓类药物需要谨慎处方,因为患者可能长期使用并且剂量可能增加。羟苯乙酯受到严格的风险评估和缓解战略方案的约束。最佳实践包括全面的患者评估、彻底的风险评估、处方药监测项目检查和透明的患者沟通。远程医疗处方受严格的法规管理,目前有临时例外。结论:受控物质对治疗各种睡眠障碍至关重要。平衡患者获得有效药物的同时尽量减少滥用和转移是至关重要的。需要进一步研究以完善风险评估工具和制定标准化方案,特别是针对非阿片类药物。远程医疗和电子处方的作用不断演变,需要不断评估和调整实践,以确保患者安全和遵守法规。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
7.00%
发文量
321
审稿时长
1 months
期刊介绍: Journal of Clinical Sleep Medicine focuses on clinical sleep medicine. Its emphasis is publication of papers with direct applicability and/or relevance to the clinical practice of sleep medicine. This includes clinical trials, clinical reviews, clinical commentary and debate, medical economic/practice perspectives, case series and novel/interesting case reports. In addition, the journal will publish proceedings from conferences, workshops and symposia sponsored by the American Academy of Sleep Medicine or other organizations related to improving the practice of sleep medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信